NovaVive Inc. - Canine

Home
Canada
Napanee, ON
NovaVive Inc. - Canine

NovaVive offers a regulator-approved immunotherapy for canine mammary cancer in the USA and Canada. NovaVive Inc.

is an animal health immunobiology company with a regulator-approved canine cancer product available to veterinarians in CA and the US.

05/28/2026

Mammary tumors are among the most commonly diagnosed tumors in female dogs, with a significant percentage being malignant.

Immunocidin® stimulates immune-mediated tumor response and may be used as a solo therapy or in combination with surgery or other treatments.

Its mechanism involves activation of immune pathways that contribute to tumor cell apoptosis.

Read the full product brochure at NovaVive.ca/products

05/21/2026

NovaVive manufactures immunotherapy products for horses, cattle, and dogs—supporting veterinarians with immune-based tools across a range of clinical applications.

Our equine portfolio includes Equimune® (U.S., Australia, New Zealand) and Settle® (U.S., Canada, Australia, New Zealand, UAE), along with Immunocidin® Equine, available in the U.S. and Canada.

For bovine use, Amplimune® is available in the U.S., Canada, New Zealand, and the UAE.

In canine applications, Immunocidin® is approved for use in the U.S. and Canada.

From performance horses to newborn calves to companion animals, NovaVive’s approach is rooted in advancing animal health through immunology.

Discover more at NovaVive.ca/products.

05/17/2026

Not every patient is an ideal candidate for surgery, particularly older dogs or those with additional health challenges.

Immunocidin® is a USDA- and CFIA-approved immunotherapeutic for the treatment of mixed mammary tumor and mammary adenocarcinoma in dogs.

Administered by intratumoral injection, it may be used as a solo therapy or alongside surgical intervention, depending on the individual case.

Treatment decisions should always be made in consultation with a licensed veterinarian. Learn more and read the full product brochure at NovaVive.ca/products.

05/11/2026

In reported data, 88% of dogs treated with Immunocidin® immunotherapy alone were tumor-free two years later.

Immunocidin® is approved for the treatment of mixed mammary tumors and mammary adenocarcinomas and may be used as a standalone option or in conjunction with surgery.

It is well tolerated, including in aged dogs and those with chronic cardiovascular or renal disease, making it a consideration for patients that may be poor surgical candidates.

Treatment is typically administered every 1 to 3 weeks and may be given prior to surgery or as a standalone treatment.

Download the product brochure and review clinical information at NovaVive.ca/products.

05/09/2026

Dagmar, a 13-year-old Standard Dachshund from Florida, was diagnosed with mammary ductal adenocarcinoma, which was surgically removed prior to treatment.

She is currently being treated with Immunocidin® immunotherapy as part of her veterinarian-directed care plan. Thirty-eight weeks after starting therapy, Dagmar was going well.

Her owner shared:
“We started her on Immunocidin®, and we’ve been so encouraged by her progress. I can only say thank you to everyone at NovaVive who helped develop this therapy, and a special thanks to Miriam Cervantes for her support along the way. Dagmar sends her thanks—she still has plenty of tail wags left.”

Every case is unique. Treatment decisions should always be made in consultation with a licensed veterinarian.

Learn more and read the full product brochure at NovaVive.ca/products

04/28/2026

Dr. Melissa McNally of Jolly Road Veterinary Hospital in Lansing, Michigan, shared a unique case involving a 16-year-old Blue-fronted Amazon parrot diagnosed with a malignant oral mass suspected to be squamous cell carcinoma.

In consultation with NovaVive, Immunocidin®, a regulator-approved immunotherapy for canine mammary tumors, was used experimentally under veterinary supervision.
Treatment began in November 2025 and was generally well-tolerated. Observations during this time suggested a gradual response of the tumor.

While Fredrica ultimately passed due to other health complications, her care team reported an extended period of quality time following diagnosis. “We were able to give Fredrica an extra 5 months from her diagnosis with Immunocidin therapy,” added Dr. McNally.

Immunocidin is approved for use in dogs. Use in other species is at the discretion of a licensed veterinarian.

Learn more at NovaVive.ca/products

04/27/2026

Across equine, bovine, and canine health, immune system function plays a critical role in how animals respond to disease challenges, environmental stressors, and management conditions.

NovaVive’s immunotherapeutics are developed using a proprietary mycobacterium cell wall fraction (MCWF) derived from Mycobacterium phlei, a non-pathogenic organism. This technology is designed to activate key components of the immune system, including macrophages and lymphocytes, supporting both innate and adaptive immune responses.

With applications across multiple species, NovaVive products provide veterinarians and producers with additional tools to support animal health through immune system activation.

Explore our full regulator-approved product portfolio and supporting information at NovaVive.ca/products.

04/25/2026

Immunocidin® is regulator-approved for treating canine mammary tumors and continues to be evaluated in research and clinical settings for additional applications, including other tumor types and palliative care.

Preliminary research and case experience suggest potential across multiple cancer types, supporting its role in broader veterinary oncology discussions.

Veterinarians and veterinary oncologists interested in experimental use can contact the NovaVive Technical Department for more information.

Case studies and additional resources are available at NovaVive.ca/canine-research.

04/20/2026

Immunocidin® is a regulator-approved immunotherapeutic for the treatment of canine mammary tumors that gives veterinarians treatment options.

It may be used as:
• A sole treatment via intratumoral administration
• A pre-surgical option to support tumor debulking
• A post-surgical approach to help address residual cells
• In combination with chemotherapy and/or surgery

This flexibility allows veterinarians to tailor treatment based on tumor presentation, patient condition, and overall clinical goals.

View product details and clinical resources at NovaVive.ca/products.

$NovaVive’s immunotherapeutics are manufactured using a proprietary mycobacterium cell wall fraction (MCWF) derived from ...$

04/16/2026

NovaVive’s immunotherapeutics are manufactured using a proprietary mycobacterium cell wall fraction (MCWF) derived from Mycobacterium phlei.

This technology has been shown to activate key immune pathways, including macrophage and lymphocyte activity, as well as cytokine signaling involved in early immune response. These mechanisms support both cell-mediated and humoral immunity across multiple species.

NovaVive’s product portfolio includes:
• Equine: Equimune® (regulator-approved in the USA, Australia, and New Zealand), Settle® (regulator-approved in the USA, Canada, Australia, New Zealand, and UAE), and Immunocidin® Equine (regulator-approved in the USA and Canada)
• Bovine: Amplimune® (regulator-approved in the USA, Canada, New Zealand, and UAE; OMRI Listed® in the USA and Canada)
• Canine: Immunocidin® (regulator-approved in the USA and Canada)

Each product is manufactured under strict quality standards, including sterility and potency testing, with regulatory batch review prior to release.

Explore the full technology and product portfolio at NovaVive.ca/technology-overview.

Address

15 Dairy Avenue
Napanee, ON
K7R1M4

Website

http://www.NovaVive.ca/

Alerts

Be the first to know and let us send you an email when NovaVive Inc. - Canine posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Want your practice to be the top-listed Clinic in Napanee?